Mice Heterozygous for a Brca 1 or Brca 2 Mutation Display Distinct Mammary Gland and Ovarian Phenotypes in Response to Diethylstilbestrol 1

Women who inherit mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are predisposed to the development of breast and ovarian cancer. We used mice with aBrca1mutation on a BALB/cJ inbred background (BALB/c mice) or a Brca2 genetic alteration on the 129/SvEv genetic background (129 B21/2 mice) to investigate potential gene-environment interactions between defects in these genes and treatment with the highly estrogenic compound diethylstilbestrol (DES). Beginning at 3 weeks of age, BALB/c, 129, and wild-type female mice were fed a control diet or a diet containing 640 ppb DES for 26 weeks. DES treatment caused vaginal epithelial hyperplasia and hyperkeratosis, uterine inflammation, adenomyosis, and fibrosis, as well as oviductal smooth muscle hypertrophy. The severity of the DES response was mouse strain specific. The estrogen-responsive 129/SvEv strain exhibited an extreme response in the reproductive tract, whereas the effect in BALB/cJ and C3H/HeN mice was less severe. TheBrca1 and Brca2 genetic alterations influenced the phenotypic response of BALB/cJ and 129/SvEv inbred strains, respectively, to DES in the mammary gland and ovary. The mammary duct branching morphology was inhibited in DES-treated BALB/c mice compared with similarly treated BALB/ c littermates. In addition, the majority of BALB/c B11/2 mice had atrophied ovaries, whereas wild-type littermates were largely diagnosed with arrested follicular development. The mammary ductal architecture in untreated 129 mice revealed a subtle inhibited branching phenotype that was enhanced with DES treatment. However, no significant differences were observed in ovarian pathology between 129 B21/1 and 129 mice. These data suggest that estrogenic compounds may modulate mammary gland or ovarian morphology in BALB/c and 129 mice. These observations are consistent with the hypothesis that compromised DNA repair processes in cells harboringBrca1 or Brca2 mutations lead to inhibited growth and differentiation compared with the proliferative response of wild-type cells to DES treatment.

[1]  R. Wiseman,et al.  Brca2‐Null Embryonic Survival is Prolonged on the BALB/c Genetic Background , 2000, Molecular Carcinogenesis.

[2]  V. Godfrey,et al.  Growth Retardation, DNA Repair Defects, and Lack of Spermatogenesis in BRCA1-Deficient Mice , 1999, Molecular and Cellular Biology.

[3]  E. Berns,et al.  Is TP53 dysfunction required for BRCA1-associated carcinogenesis? , 1999, Molecular and Cellular Endocrinology.

[4]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[5]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[6]  B. Ponder,et al.  Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. , 1999, Molecular cell.

[7]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[8]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[9]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[10]  H. Gardner,et al.  Mammary gland development, reproductive history, and breast cancer risk. , 1999, Cancer research.

[11]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[12]  Yanfen Hu,et al.  Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1. , 1999, Genes & development.

[13]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[14]  V. Godfrey,et al.  Mammary tumor formation in p53- and BRCA1-deficient mice. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  R. Tennant,et al.  Genetically altered mouse models for identifying carcinogens. , 1999, IARC scientific publications.

[16]  T. Ouchi,et al.  The BRCA2 gene product functionally interacts with p53 and RAD51. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Degenhardt,et al.  Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis , 1998, Nature Genetics.

[18]  R. White,et al.  BRCA1 is associated with the centrosome during mitosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Peto,et al.  p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours , 1998, Oncogene.

[20]  P. Hartge,et al.  Cancer risk in women exposed to diethylstilbestrol in utero. , 1998, JAMA.

[21]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[22]  B. Ponder,et al.  Oral Contraceptives and the Risk of Hereditary Ovarian Cancer , 1998 .

[23]  P. Hasty,et al.  Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. , 1998, Cancer research.

[24]  D. Robinson.  The International Life Sciences Institute's Role in the Evaluation of Alternative Methodologies for the Assessment of Carcinogenic Risk , 1998, Toxicologic pathology.

[25]  J. Haseman,et al.  The National Toxicology Program Evaluation of Genetically Altered Mice as Predictive Models for Identifying Carcinogens , 1998, Toxicologic pathology.

[26]  O. Olopade,et al.  Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. , 1998, Journal of the National Cancer Institute.

[27]  Y. Chen,et al.  The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[29]  L. Bennett,et al.  Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice , 1998, Oncogene.

[30]  M. Stratton,et al.  The genetics of breast cancer susceptibility. , 1998, Annual review of genetics.

[31]  Y. Houvras,et al.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl , 1997, Nature.

[32]  B. Henderson,et al.  Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? , 1997, Cancer research.

[33]  Chun-Fang Xu,et al.  Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.

[34]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[35]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[36]  L. Bennett,et al.  Brca1 is expressed independently of hormonal stimulation in the mouse ovary. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[37]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[38]  A. Futreal,et al.  BRCA1 expression is not directly responsive to estrogen , 1997, Oncogene.

[39]  J. Russo,et al.  Toward a unified concept of mammary carcinogenesis. , 1997, Progress in clinical and biological research.

[40]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[41]  K. Gelmon,et al.  Premenopausal breast cancer after in-utero exposure to stilboestrol , 1996, The Lancet.

[42]  B. Koller,et al.  Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities , 1996, Nature Genetics.

[43]  J. Yager,et al.  Molecular mechanisms of estrogen carcinogenesis. , 1996, Annual review of pharmacology and toxicology.

[44]  P. Leder,et al.  Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. , 1995, Genes & development.

[45]  H. Nguyen,et al.  Hormone-dependent regulation of BRCA1 in human breast cancer cells. , 1995, Cancer research.

[46]  R. Newbold.  Cellular and molecular effects of developmental exposure to diethylstilbestrol: implications for other environmental estrogens. , 1995, Environmental health perspectives.

[47]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[48]  K. Nelson,et al.  Exposure to diethylstilbestrol during a critical developmental period of the mouse reproductive tract leads to persistent induction of two estrogen-regulated genes. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[49]  A. Lupulescu.  Estrogen use and cancer risk: a review. , 2009, Experimental and clinical endocrinology.

[50]  T. Heeren,et al.  Breast cancer in mothers prescribed diethylstilbestrol in pregnancy: Further follow‐up , 1993, JAMA.

[51]  M. Marselos,et al.  Diethylstilboestrol: I, Pharmacology, Toxicology and carcinogenicity in humans. , 1992, European journal of cancer.

[52]  M. Marselos,et al.  Diethylstilboestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals. , 1992, European journal of cancer.

[53]  J. Russo,et al.  Morphology and Development of the Rat Mammary Gland , 1989 .

[54]  D. L. Greenman,et al.  Influence of age on induction of mammary tumors by diethylstilbestrol in C3H/HeN mice with low murine mammary tumor virus titer. , 1986, Journal of the National Cancer Institute.

[55]  A. B. Barnes,et al.  Breast cancer in mothers given diethylstilbestrol in pregnancy. , 1984, The New England journal of medicine.

[56]  M. Metzler,et al.  Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity. , 1984, Molecular pharmacology.

[57]  W. Thompson,et al.  Cancer risk among women exposed to exogenous estrogens during pregnancy. , 1984, Journal of the National Cancer Institute.

[58]  R. Kodell,et al.  Neoplastic and nonneoplastic responses to chronic feeding of diethylstilbestrol in C3H mice. , 1984, Journal of toxicology and environmental health.

[59]  H. Bern,et al.  Growth of mouse mammary glands after neonatal sex hormone treatment. , 1982, Journal of the National Cancer Institute.

[60]  V. Beral,et al.  Randomised trial of high doses of stilboestrol and ethisterone in pregnancy: long-term follow-up of mothers. , 1980, British medical journal.

[61]  H. Bern,et al.  Cervicovaginal and mammary gland abnormalities in BALB/cCrgl mice treated neonatally with progesterone and estrogen, alone or in combination. , 1979, Cancer research.

[62]  M. Bibbo,et al.  A twenty-five-year follow-up study of women exposed to diethylstilbestrol during pregnancy. , 1978, The New England journal of medicine.

[63]  H. Nagasawa,et al.  Prolactin and murine mammary tumorigenesis: a review. , 1977, Cancer research.

[64]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. , 1971, The New England journal of medicine.

[65]  G. Gass,et al.  CARCINOGENIC DOSE-RESPONSE CURVE TO ORAL DIETHYLSTILBESTROL. , 1964, Journal of the National Cancer Institute.

[66]  Bernice W. Polemis.  Nonparametric Statistics for the Behavioral Sciences , 1959 .